The impact of nirsevimab prophylaxis on RSV hospitalizations: a real-world cost-benefit analysis in Tuscany, Italy

BackgroundRespiratory Syncytial Virus (RSV) is the leading cause of hospitalizations in infants. The approval of nirsevimab, a long-acting monoclonal antibody, has extended the potential for RSV prophylaxis to all infants. This study assesses the cost–benefit of various Nirsevimab prophylaxis strate...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Vieri Lastrucci, Martina Pacifici, Giorgia Alderotti, Monia Puglia, Elettra Berti, Federica Barbati, Lorenzo Lodi, Silvia Boscia, Francesco Nieddu, Giuseppe Indolfi, Diego Peroni, Marco Martini, Chiara Azzari, Fabio Voller, Maria Moriondo, Silvia Ricci
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2025-07-01
Ráidu:	Frontiers in Public Health
Fáttát:	respiratory syncytial virus (RSV) immunization prevention nirsevimab hospitalizations cost–benefit analysis
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fpubh.2025.1604331/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!